Literature DB >> 22333747

Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review.

Michael-John S Milloy, Brandon D L Marshall, Thomas Kerr, Jane Buxton, Tim Rhodes, Julio Montaner, Evan Wood.   

Abstract

OBJECTIVE: To systematically review factors associated with HIV disease progression among illicit drug users, focusing on exposures exogenous to individuals that likely shape access and adherence to HIV treatment.
DESIGN: A systematic review of peer-reviewed English-language studies among HIV-seropositive illicit drug users with at least one of these endpoint of interest: a diagnosis of AIDS; death; changes/differences in CD4 cell counts; or changes/differences in plasma HIV-1 RNA levels.
METHODS: Articles were included if they reported factors associated with an outcome of interest among a group of illicit drug users. Studies were identified, screened and selected using systematic methods.
RESULTS: Of 2668 studies matching the search criteria, 58 (2%) met the inclusion criteria, all but one from North America or western Europe. Overall, 41 (71%) studies contained significant individual-level clinical characteristics or behaviors (e.g. illicit drug use) associated with disease progression. Fifteen studies (26%) identified significant social, physical, economic or policy-level exposures, including incarceration, housing status or lack of legal income.
CONCLUSION: Although past studies demonstrate important environmental exposures that appear to shape access to care and subsequent disease progression, the limited literature to examine these factors demonstrates the need for future research to consider risk environment characteristics and the role they may play in shaping health outcomes from HIV infection among drug users through determining access and adherence to evidence-based care.

Entities:  

Mesh:

Year:  2012        PMID: 22333747      PMCID: PMC3955099          DOI: 10.1097/QAD.0b013e32835221cc

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  91 in total

1.  Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E-rosette formation and antigenic marker expression.

Authors:  R M Donahoe; J K Nicholson; J J Madden; F Donahoe; D A Shafer; D Gordon; P Bokos; A Falek
Journal:  Clin Immunol Immunopathol       Date:  1986-11

2.  A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.

Authors:  Grace E Macalino; Joseph W Hogan; Jennifer A Mitty; Lauri B Bazerman; Alison K Delong; Helen Loewenthal; Angela M Caliendo; Timothy P Flanigan
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

3.  Low serum thiol levels predict shorter times-to-death among HIV-infected injecting drug users.

Authors:  M Marmor; P Alcabes; S Titus; K Frenkel; K Krasinski; A Penn; R W Pero
Journal:  AIDS       Date:  1997-09       Impact factor: 4.177

4.  Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users.

Authors:  C Piketty; P Castiel; P Giral; J P Lhomme; D Boubilley; C Olievenstein; F Lert; M D Kazatchkine
Journal:  AIDS Care       Date:  1999-08

5.  Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial.

Authors:  Karina M Berg; Alain Litwin; Xuan Li; Moonseong Heo; Julia H Arnsten
Journal:  Drug Alcohol Depend       Date:  2010-09-15       Impact factor: 4.492

6.  Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users.

Authors:  M Prins; I H Hernández Aguado; R P Brettle; J R Robertson; B Broers; N Carré; D J Goldberg; R Zangerle; R A Coutinho; A van den Hoek
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

7.  Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression.

Authors:  Liselotte van Asten; Maria Prins
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

8.  Temporal trends in the progression of human immunodeficiency virus disease in a cohort of drug users.

Authors:  M P Webber; E E Schoenbaum; M N Gourevitch; D Buono; C J Chang; R S Klein
Journal:  Epidemiology       Date:  1998-11       Impact factor: 4.822

9.  Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study.

Authors:  L H Omland; P Jepsen; N Weis; P B Christensen; A L Laursen; H Nielsen; H Krarup; H T Sørensen; N Obel
Journal:  J Viral Hepat       Date:  2009-08-26       Impact factor: 3.728

10.  Accessing antiretroviral therapy following release from prison.

Authors:  Jacques Baillargeon; Thomas P Giordano; Josiah D Rich; Z Helen Wu; Katherine Wells; Brad H Pollock; David P Paar
Journal:  JAMA       Date:  2009-02-25       Impact factor: 56.272

View more
  42 in total

1.  Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs.

Authors:  Jiaming Liang; Ekaterina Nosova; Hudson Reddon; Seonaid Nolan; Eugenia Socías; Rolando Barrios; M-J Milloy
Journal:  AIDS       Date:  2020-07-15       Impact factor: 4.177

2.  Drug use, hepatitis C, and service availability: perspectives of incarcerated rural women.

Authors:  Michele Staton-Tindall; J Matthew Webster; Carrie B Oser; Jennifer R Havens; Carl G Leukefeld
Journal:  Soc Work Public Health       Date:  2015

3.  Residential Eviction and Risk of Detectable Plasma HIV-1 RNA Viral Load Among HIV-Positive People Who Use Drugs.

Authors:  Mary Clare Kennedy; Thomas Kerr; Ryan McNeil; Surita Parashar; Julio Montaner; Evan Wood; M-J Milloy
Journal:  AIDS Behav       Date:  2017-03

4.  Longer duration of homelessness is associated with a lower likelihood of non-detectable plasma HIV-1 RNA viral load among people who use illicit drugs in a Canadian setting.

Authors:  Jane Loh; Mary Clare Kennedy; Evan Wood; Thomas Kerr; Brandon Marshall; Surita Parashar; Julio Montaner; M-J Milloy
Journal:  AIDS Care       Date:  2016-06-01

5.  Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial.

Authors:  Lisa R Metsch; Daniel J Feaster; Lauren Gooden; Tim Matheson; Maxine Stitzer; Moupali Das; Mamta K Jain; Allan E Rodriguez; Wendy S Armstrong; Gregory M Lucas; Ank E Nijhawan; Mari-Lynn Drainoni; Patricia Herrera; Pamela Vergara-Rodriguez; Jeffrey M Jacobson; Michael J Mugavero; Meg Sullivan; Eric S Daar; Deborah K McMahon; David C Ferris; Robert Lindblad; Paul VanVeldhuisen; Neal Oden; Pedro C Castellón; Susan Tross; Louise F Haynes; Antoine Douaihy; James L Sorensen; David S Metzger; Raul N Mandler; Grant N Colfax; Carlos del Rio
Journal:  JAMA       Date:  2016-07-12       Impact factor: 56.272

6.  Medication adherence challenges among HIV positive substance abusers: the role of food and housing insecurity.

Authors:  Hilary L Surratt; Catherine L O'Grady; Maria A Levi-Minzi; Steven P Kurtz
Journal:  AIDS Care       Date:  2014-10-14

Review 7.  Challenges in managing HIV in people who use drugs.

Authors:  Adeeba Kamarulzaman; Frederick L Altice
Journal:  Curr Opin Infect Dis       Date:  2015-02       Impact factor: 4.915

8.  Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting.

Authors:  Brenden Joseph; Thomas Kerr; Cathy M Puskas; Julio Montaner; Evan Wood; M-J Milloy
Journal:  AIDS Care       Date:  2015-04-27

9.  Development of a Multi-Target Contingency Management Intervention for HIV Positive Substance Users.

Authors:  Maxine Stitzer; Donald Calsyn; Timothy Matheson; James Sorensen; Lauren Gooden; Lisa Metsch
Journal:  J Subst Abuse Treat       Date:  2016-08-28

Review 10.  The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs.

Authors:  Stefan D Baral; Susanne Strömdahl; Chris Beyrer
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.